SCHEMBL23877502

SCHEMBL23877502

COC(=O)c1cc(C(F)(F)F)ccc1NS(=O)(=O)CS(C)(=O)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFTR P13569 1/20 0.52
▸ KDM1A O60341 2/20 0.44
▸ KDM4E B2RXH2 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.41
▸ PARP14 Q460N5 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ MCL1 Q07820 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CES2 O00748 1/20 0.39
▸ MRGPRX4 Q96LA9 1/20 0.39
▸ ERAP2 Q6P179 1/20 0.38
▸ ERAP1 Q9NZ08 1/20 0.38
▸ LIPC P11150 1/20 0.38
▸ LIPG Q9Y5X9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3744782 0.85 CFTR (0.55) CFTRKDM1AKDM4EHPGDHSD17B10
SCHEMBL3738491 0.82 CFTR (0.54) CFTRKDM1AKDM4EALDH1A1MAPT
SCHEMBL23141323 0.81 CFTR (0.52) CFTRKDM1AKDM4EALDH1A1MAPT
SCHEMBL23141168 0.79 KDM1A (0.61) CFTRKDM1AMEN1KMT2AACLY
SCHEMBL3528690 0.77 KDM1A (0.61) KDM1AMAPTMEN1LMNAKMT2A
SCHEMBL5833791 0.76 CFTR (0.61) CFTRKDM4EALDH1A1MAPTHPGD
SCHEMBL3378756 0.76 KIF11 (0.54) CFTRKDM1AKDM4EHSD17B10SMN1; SMN2
SCHEMBL23141176 0.75 ALDH1A1 (0.61) CFTRKDM1AKDM4EALDH1A1MAPT
SCHEMBL15754620 0.75 NOTUM (0.52) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL23141181 0.75 KDM1A (0.62) KDM1AKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 — — US disclosed
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO, INC. 2024-12-12 — — US disclosed
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2024-07-30 — — US disclosed
EP-3796975-B1 SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO INC (US) 2023-08-30 — — EP disclosed
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES GILEAD SCIENCES, INC. 2022-02-24 — — US disclosed
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives THE LIVER COMPANY INC. (US) 2021-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B CFTR 1119/4885KDM1A 2735/4885KDM4E 3158/4885
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B CFTR 1119/4885KDM1A 2735/4885KDM4E 3158/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 CFTR 869/4885KDM1A 4072/4885KDM4E 3921/4885
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B CFTR 1119/4885KDM1A 2735/4885KDM4E 3158/4885
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B CFTR 1119/4885KDM1A 2735/4885KDM4E 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback